Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics

Phase 1 Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03094897

Enrollment

Registered

2017-03-29

Start date

2017-04-20

Completion date

2020-12-31

Last updated

2017-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms, Prostatic Neoplasms

Keywords

Breast Neoplasms,Prostatic Neoplasms

Brief summary

The purpose of this study is to determine whether 18F-Al-NOTA-MATBBN is safety and effective for cancer diagnosis.

Detailed description

Observe radiation dose to healthy volunteers and patients; the correlation between integrin level and tumor/metastases uptake.

Interventions

DRUG18F-Al-NOTA-MATBBN PET/CT

18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.

DEVICEPET/CT

Imaging with 18F-Al-NOTA-MATBBN PET/CT.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Masking description

Open Label

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Volunteers or patients with age more than 18 yeas; 2. The patients have been diagnosed with cancer or suspected with cancer; 3. It must fulfill the ethical requirements and subjects have signed an informed consent.

Exclusion criteria

1. Pregnancy or nursing mothers; 2. Having drugs or alcohol dependence; 3. Hypersensitive to the active or inactive ingredients of the study drug; 4. Having attended other drug clinical trials within three months; 5. Cardiac functional insufficiency; 6. Hepatic and renal function insufficiency; 7. Hypertensive patients with serious complications; 8. Endangering the safety of life.

Design outcomes

Primary

Measure	Time frame	Description
Standardized uptake value of 18F-Al-NOTA-MATBBN in malignant lesions	1 day	The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in malignant lesions will be measured.

Secondary

Measure	Time frame	Description
Adverse events collection	1 week	Adverse events within 1 week after the injection and scanning of patients and patients will be followed and assessed.

Contacts

Primary Contactchunjing Yu, PhD,MD

ycj_wxd1978@163.com0510-88682783

Backup Contactmin Yang, PhD

ymzfk@163.com0510-88682783

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026